Rubicon Research IPO Analyzed

Rubicon Research, a pharmaceutical company focused on developing and selling medicines, is going public. They are trying to raise money by selling shares to the public. This is called an Initial Public Offering, or IPO. They aim to collect ₹1,377.50 crore from investors. This is a big step for the company and could be a good opportunity for investors.

Key Points

• Rubicon Research is selling shares to raise ₹1,377.50 crore.
• ₹500 crore from a new share sale and ₹877.50 crore from selling shares already owned.
• Shares priced between ₹461 and ₹485 per share, minimum 30 shares per lot.
• Investors can bid from October 10th to October 13th, 2025.
• Shares will list on BSE and NSE on October 16, 2025.
• Funds will be used for debt repayment and growth opportunities.

The IPO is divided into two parts. First, Rubicon Research will sell 1.3 million new shares for ₹500 crore. Second, existing shareholders, primarily General Atlantic Singapore, will sell up to 18.1 million shares for ₹877.50 crore. Investors can bid for shares in lots of 30, meaning you need to buy at least 30 shares. The price of each share will be between ₹461 and ₹485.

Who can invest? The company is aiming to sell 75% of the shares to big investors who already own the company, 15% to regular investors, and 10% to everyday buyers. This means large investors will likely get the first chance to buy the most shares. A retail investor wanting to buy just one lot of 30 shares would need to spend around ₹14,550.

What’s the grey market saying? The “grey market” is an unofficial market where shares are traded before they’re officially listed. Right now, shares are being traded at ₹565, which is a 16.49% premium over the highest price the company is offering. This suggests investors are optimistic about the company’s future.

What will the money be used for? Rubicon Research plans to use the money it raises to pay off its debts and to grow its business through buying other companies and other strategies. They’ve stated this clearly in their prospectus.

About Rubicon Research: Rubicon Research has been developing medicines since 2012. They make and sell medicines, mostly in the United States. They have factories in India and research centers in India and Canada and have received many approvals for their medicines.

“A successful IPO is a pivotal moment, marking the company’s transition to the public market and offering investors the opportunity to participate in its future growth.”